醒脑静注射液辅助治疗阿替普酶静脉溶栓后脑梗死患者的恢复效果研究
|
摘要
目的:研究醒脑静注射液辅助治疗阿替普酶静脉溶栓后脑梗死患者的恢复效果。方法:研究纳入92例脑梗死患者,均由医院2016年6月—2018年2月收治,患者自愿参与研究,并根据随机数字表法将其分为两组,对照组患者(46例)阿替普酶静脉溶栓治疗,观察组患者(46例)在对照组患者治疗基础上另予以醒脑静注射液治疗,比较两组患者治疗后有效率、治疗前后NIHSS评分及ADL评分、血清CRP、HCT及FIB水平、不良反应情况及满意度。结果:观察组患者治疗总有效率(95.65%)高于对照组(82.61%),P<0.05;观察组患者治疗后NIHSS评分低于对照组(P<0.05);ADL评分高于对照组(P<0.05);治疗前两组患者血清C反应蛋白(CRP)、红细胞比容(HCT)、纤维蛋白原(FIB)比较无统计学差异(P>0.05),与对照组相比,治疗后观察组患者血清CRP、HCT、FIB水平显著降低(P<0.05);观察组患者不良反应率为4.35%,对照组不良反应率为6.52%,两组不良反应率差异无统计学意义(P>0.05);观察组患者治疗满意率(95.65%)显著高于对照组(80.43%),具有统计学差异(P<0.05)。结论:醒脑静注射液辅助治疗阿替普酶静脉溶栓后脑梗死临床疗效显著,可显著提升患者治疗有效率,改善患者神经缺损情况、提高患者日常生活能力,不良反应率低,且患者治疗满意度高,值得临床推广及应用。
Objective:To study the effect of Xingnaojing Injection on the recovery of cerebral infarction patients after intravenous thrombolysis with alteplase. Methods:This study included 92 patients with cerebral infarction in our hospital from June 2016 to February 2018. According to random number table method, the patients were divided into two groups. The control group(46 cases) used intravenous thrombolysis enzyme treatment. The observation group(46 cases) on the basis was given Xingnaojing Injection. We compared two groups' efficient and NIHSS scores and ADL scores before and after treatment, serum CRP, HCT and FIB, adverse reactions and satisfaction level. Results:The total effective rate(95.65%) in the observation group was higher than that in the control group(82.61%)(P<0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group(P<0.05). ADL score was higher than that of the control group(P<0.05). There were no significant differences in serum CRP, HCT or FIB between the two groups before treatment(P>0.05). Serum CRP, HCT and FIB levels were significantly lower in the observation group after treatment than those in the control group(P<0.05). The adverse reaction rate of patients in the observation group was 4.35%, while that in the control group was 6.52%. There was no significant difference in the adverse reaction rate between the two groups(P>0.05). The treatment satisfaction rate(95.65%) in the observation group was significantly higher than that in the control group(80.43%)with statistical difference(P<0.05). Conclusion:Xingnaojing Injection has a significant clinical effect in treating cerebral infarction after intravenous Xingnaojing Injection, which can significantly improve the treatment efficiency, the situation of nerve defects in patients and the ability of daily life of patients, with a low rate of adverse reactions, and a high degree of patient satisfaction with treatment, which is worthy of clinical promotion and application.
Objective:To study the effect of Xingnaojing Injection on the recovery of cerebral infarction patients after intravenous thrombolysis with alteplase. Methods:This study included 92 patients with cerebral infarction in our hospital from June 2016 to February 2018. According to random number table method, the patients were divided into two groups. The control group(46 cases) used intravenous thrombolysis enzyme treatment. The observation group(46 cases) on the basis was given Xingnaojing Injection. We compared two groups' efficient and NIHSS scores and ADL scores before and after treatment, serum CRP, HCT and FIB, adverse reactions and satisfaction level. Results:The total effective rate(95.65%) in the observation group was higher than that in the control group(82.61%)(P<0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group(P<0.05). ADL score was higher than that of the control group(P<0.05). There were no significant differences in serum CRP, HCT or FIB between the two groups before treatment(P>0.05). Serum CRP, HCT and FIB levels were significantly lower in the observation group after treatment than those in the control group(P<0.05). The adverse reaction rate of patients in the observation group was 4.35%, while that in the control group was 6.52%. There was no significant difference in the adverse reaction rate between the two groups(P>0.05). The treatment satisfaction rate(95.65%) in the observation group was significantly higher than that in the control group(80.43%)with statistical difference(P<0.05). Conclusion:Xingnaojing Injection has a significant clinical effect in treating cerebral infarction after intravenous Xingnaojing Injection, which can significantly improve the treatment efficiency, the situation of nerve defects in patients and the ability of daily life of patients, with a low rate of adverse reactions, and a high degree of patient satisfaction with treatment, which is worthy of clinical promotion and application.
引文
[1] 戈蕾,赵玉晓,常永霞,等.依达拉奉联合rTMS对脑梗死患者自由基及神经功能的影响[J].海南医学院学报,2017,23(4):504-506.
[2] 吕艳芳.瑞舒伐他汀联合普罗布考治疗老年期脑梗死对患者颈动脉粥样硬化与血脂及血浆炎性因子的影响[J].中国实用神经疾病杂志,2017,20(4):110-112.
[3] 蒋飞霞,苏宏业,唐华民,等.2型糖尿病长期治疗后合并冠心病及脑梗死的多因素分析[J].重庆医学,2018,47(17):2266-2269.
[4] 徐霁华,秦伟,袁俊亮,等.超早期应用重组组织型纤溶酶原激活剂静脉溶栓治疗超高龄患者脑梗死[J].山东医药,2017,57(15):68-70.
[5] 蔡传萍,金冬梅,录欣欣,等.功能性电刺激治疗对脑梗死大鼠神经功能和缺血半暗带GSK-3β蛋白的影响[J].中国康复医学杂志,2018,33(6):647-652.
[6] 张合亮,刘美利,孙刚,等.Solumbra血管内再通技术治疗急性大动脉闭塞性脑梗死[J].中华老年医学杂志,2018,37(2):148-153.
[7] 田燕,方煜,胡明,等.丹参川芎嗪注射液与参芎葡萄糖注射液治疗脑梗死的成本-效果分析[J].中国药房,2018,29(4):487-492.
[8] 胡新国,罗文婷,孙刚彪,等.巴曲酶注射液联合依达拉奉对老年脑梗死患者神经功能及血清相关因子的影响[J].中华老年心脑血管病杂志,2018,20(8):840-843.
[9] 刘峥,张尚明,陈其钻,等.临时阻断夹短暂误夹动脉瘤毗邻分支导致脑梗死的临床分析[J].中华神经外科杂志,2018,34(2):162-165.
[10] 邬刚,李建辉,战丽萍,等.丁苯酞注射液对伴有认知障碍的脑梗死急性期患者脑血流灌注和认知功能的影响[J].中华神经医学杂志,2018,17(5):484-490.
[11] 侯焕峰,李如娟,马晓辉,等.微创减压治疗恶性大脑中动脉脑梗死的临床回顾研究[J].首都医科大学学报,2018,39(4):546-551.
[12] 董丹,李佳佳,尚宜星,等.丹红注射液辅助西药对糖尿病合并脑梗死患者血管内皮功能的影响及疗效研究[J].中华中医药学刊,2018,36(3):712-715.
[13] 邓世芳,陈威,卞伟,等.从MMP-9水平研究芪棱汤对动脉粥样硬化性脑梗死患者的影响[J].广州中医药大学学报,2018,35(5):769-773.
[14] 徐运.加强无症状脑梗死的规范化诊疗[J].中华神经科杂志,2018,51(9):664-665.
[15] 肖云,彭拥军.电针对急性期脑梗死患者血清HIF-1α、VEGF水平的影响[J].南京中医药大学学报,2018,34(2):128-131.
[16] 陈娜,李虹,陆连生,等.阿替普酶静脉溶栓同时联合丁苯酞注射液治疗急性脑梗死的疗效观察[J].河北医药,2017,39(1):69-71.
[17] 李鸿飞,徐冬娟,张为强,等.超早期应用阿替普酶静脉溶栓对脑梗死患者临床转归的影响[J].中国医药导报,2017,14(14):64-67.
[18] 洪震,李泽钊,贾秀凤,等.人尿激肽原酶联合阿替普酶静脉溶栓对急性脑梗死患者的神经系统、日常生活能力及不良反应的影响[J].河北医药,2017,39(13):1978-1980.
[19] 冯桂平.阿替普酶静脉溶栓联合丁苯酞对超早期脑梗死的临床疗效分析[J].世界临床医学,2017,11(20):88-89.
[20] 鲁文先,苏毅鹏,陈金波,等.急性脑梗死患者阿替普酶静脉溶栓的疗效及出血性转化影响因素分析[J].脑与神经疾病杂志,2017,25(1):29-33.
[21] 肖小华,徐玮,黄正义,等.9天内再次阿替普酶溶栓的复发性急性脑梗死1例报告[J].中国神经精神疾病杂志,2017,43(9):570-572.
[22] 李娇红,程锦楠,李作孝,等.丹参川芎嗪注射液对急性脑梗死患者血清HIF-1α、Caspase-3及血尿酸水平影响研究[J].中华中医药学刊,2018,36(2):435-437.
[23] 杨巧沛,戚梦茴,官最一,等.醒脑静注射液对急性脑梗死患者认知功能恢复的影响[J].中国生化药物杂志,2017,37(3):156-158.
[24] 王承明,卢志刚.醒脑静注射液对老年急性脑梗死血瘀证患者的疗效及血液流变学的影响[J].中国老年学杂志,2017,37(12):2910-2912.
[25] 魏雪涛,刘海花,马如静,等.醒脑静联合阿替普酶治疗急性缺血性脑卒中对神经功能及相关因子的影响[J].河北医药,2016,38(14):2155-2157.
[2] 吕艳芳.瑞舒伐他汀联合普罗布考治疗老年期脑梗死对患者颈动脉粥样硬化与血脂及血浆炎性因子的影响[J].中国实用神经疾病杂志,2017,20(4):110-112.
[3] 蒋飞霞,苏宏业,唐华民,等.2型糖尿病长期治疗后合并冠心病及脑梗死的多因素分析[J].重庆医学,2018,47(17):2266-2269.
[4] 徐霁华,秦伟,袁俊亮,等.超早期应用重组组织型纤溶酶原激活剂静脉溶栓治疗超高龄患者脑梗死[J].山东医药,2017,57(15):68-70.
[5] 蔡传萍,金冬梅,录欣欣,等.功能性电刺激治疗对脑梗死大鼠神经功能和缺血半暗带GSK-3β蛋白的影响[J].中国康复医学杂志,2018,33(6):647-652.
[6] 张合亮,刘美利,孙刚,等.Solumbra血管内再通技术治疗急性大动脉闭塞性脑梗死[J].中华老年医学杂志,2018,37(2):148-153.
[7] 田燕,方煜,胡明,等.丹参川芎嗪注射液与参芎葡萄糖注射液治疗脑梗死的成本-效果分析[J].中国药房,2018,29(4):487-492.
[8] 胡新国,罗文婷,孙刚彪,等.巴曲酶注射液联合依达拉奉对老年脑梗死患者神经功能及血清相关因子的影响[J].中华老年心脑血管病杂志,2018,20(8):840-843.
[9] 刘峥,张尚明,陈其钻,等.临时阻断夹短暂误夹动脉瘤毗邻分支导致脑梗死的临床分析[J].中华神经外科杂志,2018,34(2):162-165.
[10] 邬刚,李建辉,战丽萍,等.丁苯酞注射液对伴有认知障碍的脑梗死急性期患者脑血流灌注和认知功能的影响[J].中华神经医学杂志,2018,17(5):484-490.
[11] 侯焕峰,李如娟,马晓辉,等.微创减压治疗恶性大脑中动脉脑梗死的临床回顾研究[J].首都医科大学学报,2018,39(4):546-551.
[12] 董丹,李佳佳,尚宜星,等.丹红注射液辅助西药对糖尿病合并脑梗死患者血管内皮功能的影响及疗效研究[J].中华中医药学刊,2018,36(3):712-715.
[13] 邓世芳,陈威,卞伟,等.从MMP-9水平研究芪棱汤对动脉粥样硬化性脑梗死患者的影响[J].广州中医药大学学报,2018,35(5):769-773.
[14] 徐运.加强无症状脑梗死的规范化诊疗[J].中华神经科杂志,2018,51(9):664-665.
[15] 肖云,彭拥军.电针对急性期脑梗死患者血清HIF-1α、VEGF水平的影响[J].南京中医药大学学报,2018,34(2):128-131.
[16] 陈娜,李虹,陆连生,等.阿替普酶静脉溶栓同时联合丁苯酞注射液治疗急性脑梗死的疗效观察[J].河北医药,2017,39(1):69-71.
[17] 李鸿飞,徐冬娟,张为强,等.超早期应用阿替普酶静脉溶栓对脑梗死患者临床转归的影响[J].中国医药导报,2017,14(14):64-67.
[18] 洪震,李泽钊,贾秀凤,等.人尿激肽原酶联合阿替普酶静脉溶栓对急性脑梗死患者的神经系统、日常生活能力及不良反应的影响[J].河北医药,2017,39(13):1978-1980.
[19] 冯桂平.阿替普酶静脉溶栓联合丁苯酞对超早期脑梗死的临床疗效分析[J].世界临床医学,2017,11(20):88-89.
[20] 鲁文先,苏毅鹏,陈金波,等.急性脑梗死患者阿替普酶静脉溶栓的疗效及出血性转化影响因素分析[J].脑与神经疾病杂志,2017,25(1):29-33.
[21] 肖小华,徐玮,黄正义,等.9天内再次阿替普酶溶栓的复发性急性脑梗死1例报告[J].中国神经精神疾病杂志,2017,43(9):570-572.
[22] 李娇红,程锦楠,李作孝,等.丹参川芎嗪注射液对急性脑梗死患者血清HIF-1α、Caspase-3及血尿酸水平影响研究[J].中华中医药学刊,2018,36(2):435-437.
[23] 杨巧沛,戚梦茴,官最一,等.醒脑静注射液对急性脑梗死患者认知功能恢复的影响[J].中国生化药物杂志,2017,37(3):156-158.
[24] 王承明,卢志刚.醒脑静注射液对老年急性脑梗死血瘀证患者的疗效及血液流变学的影响[J].中国老年学杂志,2017,37(12):2910-2912.
[25] 魏雪涛,刘海花,马如静,等.醒脑静联合阿替普酶治疗急性缺血性脑卒中对神经功能及相关因子的影响[J].河北医药,2016,38(14):2155-2157.